小牛脾提取物注射液联合化疗治疗晚期非小细胞肺癌的临床疗效  

Efficacy of calf spleen extraction injection combined chemotherapy in the treatment of advanced nonsmall cell lung cancer

作　　者：孙宇萍[1] 王季颖[1] 吕梅君[1] 周彩存[1] 

机构地区：[1]同济大学附属上海市肺科医院肿瘤科,上海200433

出　　处：《中国癌症杂志》2008年第6期442-445,共4页China Oncology

摘　　要：背景与目的:肺癌的发生、发展与机体的免疫功能状况密切相关,恶性肿瘤患者存在明显的免疫功能紊乱,主要表现为细胞免疫功能下降。本研究评价采用小牛脾提取物注射液(斯普林)辅助多西他赛(泰素帝)+顺铂联合化疗方案(DP)治疗晚期非小细胞肺癌的疗效。方法:用信封法将93例晚期非小细胞肺癌患者随机分为两组:斯普林组(48例)采用斯普林联合泰素帝+顺铂治疗;对照组(45例)单用泰素帝+顺铂治疗。斯普林组于开始使用DP方案时即行斯普林10 ml/d(含25 mg多肽)静脉点滴,连续应用10 d。分别于治疗前后对患者外周血白细胞、血小板、血红蛋白水平、肝肾功能、食欲、消化道反应、体重、Karnofsky评分、免疫功能、疗效进行评价。结果:斯普林组及对照组的总有效率分别为46.67%及30.23%,两组间差异有显著性(P=0.023)。斯普林组及对照组中位生存时间分别为10.1个月及8.3个月(P=0.035)。1年生存率在斯普林组及对照组分别为52.9%及39.4%(P=0.038)。斯普林组的临床症状及生活质量显著改善,与对照组比较差异有显著性(P<0.05)。斯普林组白细胞、血小板及血红蛋白水平减少程度均好于对照组。免疫指标NK细胞活性,及CD3、CD4、CD8阳性细胞百分率,CD4/CD8比值显著提高,两组比较差异有显著性(P<0.05)。结论:斯普林联合DP方案治疗晚期非小细胞肺癌可以增加疗效,减轻骨髓毒性、疼痛及消化道反应,提高机体免疫力,提高患者生存质量和化疗耐受性,值得临床推广。Background and purpose： The occurrence and development of ltmg cancer are closely correlated with the immune function in the human body.The patients with malignant tumors have shown a disorder of immune function,especially in terms of loss of cellular immune function. The purpose of this study was to investigate the possible auxiliary effect of sipulin in the treatment of advanced non-small-cell lung cancer （NSCLC）. methods： Ninety-three patients were randomly divided into two groups： sipulin group： sipulin plus docetaxel ＋ cisplatin; control group： only administered docetaxel ＋ cisplatin. The leukocyte, haemoglobin and platelet,toxicity of digestive tract, body weight, Karnofsky status and efficacy of those patients were evaluated before and after therapy, respectively. Results： Overall response rates were 46.67% and 30.23% （P=0.023） in sipulin group and control group, respectively. The median survival time was 10.1months versus 8.3 months （P=0.035） in sipulin group and control group, respectively. The 1-year survival rate for sipulin group and control group was 52.9% versus 39.4% （P=0.038）, respectively. The clinical efficacy and the fiequence of leukocyte reduction were better in sipulin group than in control group,the quality of life and clinical symptom of the patients in sipulin group were improved more significantly than those in control group （P〈 0.05）, the value of CD3, CD4, CD3/CD4 and NK in sipulin group were significantly higher than in control group （P〈0.05）. Conclusions： Sipulin plus DP regimen can improve the efficacy of the treatment,reduce the chemotherapy related toxicities of digestive tract and bone marrow, enhance the immune function and improve the quality of life and the tolerance of chemotherapy of NSCLC patients.

关 键 词：小牛脾提取物注射液 多西他赛 顺铂 非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]